These cardiac benefits of SGLT2 inhibitors are mediated by a switch in myocardial fuel metabolism away from glucose metabolism toward ketone bodies, free fatty acid, and branched-chain amino acid, which increased myocardial adenosine triphosphate content and enhanced myocardial work efficiency.[18] Shao et al reported that the SGLT2 inhibitor empagliflozin can ameliorate cardiac structural as well as improve mitochondrial biogenesis and function.[19] Thus, SGLT2 inhibitors might adverse LV remodeling by enhancing myocardial energetics in DCM patients. Here, SLC5A2 is linked to familial dilated cardiomyopathy.